Pzifer’s kidney cancer drug Inlyta receives draft approval from NICE.
The National Institute for Health and Care Excellence (NICE) has issued draft approval for Pfizer’s Inlyta, giving the kidney cancer drug an initial yes following the pharma company’s appeal against an earlier, negative decision.
Recent draft guidance issued by NICE offers initial endorsement for the axitinib-based therapy as a treatment for renal cell carcinoma; welcome news for Pfizer after the medicines regulator originally declined to approve the drug.
Pfizer appealed against the initial lack of interest, supplying NICE with further information on the drug’s success and proposing a patient-access scheme that have now prompted draft approval from the regulator.
Inlyta will be subject to public consultation before any final recommendations are confirmed, although Pfizer is hopeful that the kidney cancer treatment will soon be available to patients on the NHS.
Professor Carol Longson, health technology evaluation director at NICE, said: “We are pleased to now be able to provisionally recommend axitinib in this draft guidance and we welcome comments on this proposal as part of the consultation.”